Description
What Is Movymia Teriparatide 20 mcg?
Movymia teriparatide is a prescription bone-forming medicine supplied as a clear, colourless solution in a 2.4 mL cartridge. Each fixed 80 microlitre dose contains 20 micrograms of teriparatide, and one cartridge provides 28 doses. Teriparatide is the active 1–34 fragment of human parathyroid hormone and stimulates new bone formation when it is given once daily.
Movymia is a biosimilar medicine authorised for adults with osteoporosis who are at increased risk of fracture. It is used in postmenopausal women, in men at increased fracture risk, and in women or men with osteoporosis associated with sustained systemic glucocorticoid treatment. It is not a pain-relief injection and it must be started and reviewed by a clinician experienced in osteoporosis care.
Movymia Teriparatide: Quick Facts
- Active substance: teriparatide, recombinant human parathyroid hormone fragment 1–34.
- Strength: 20 micrograms in each fixed 80 microlitre dose.
- Cartridge: 2.4 mL containing 600 micrograms, sufficient for 28 doses.
- Route: subcutaneous injection in the thigh or abdomen.
- Frequency: once daily, at about the same time each day.
- Device: exclusively the reusable Movymia Pen with a compatible new needle.
- Maximum course: 24 months in total over the patient’s lifetime.
- Storage: refrigerated at 2–8°C, protected from light; never freeze.
- Prescription status: prescription only; injection training is essential.
How Movymia Builds Bone
Bone is constantly remodelled. When teriparatide is delivered intermittently once a day, it preferentially stimulates osteoblast activity, the cells responsible for making new bone. This can increase bone mineral density and reduce the likelihood of certain fragility fractures. The European authorisation notes significant reductions in vertebral and non-vertebral fractures in postmenopausal women, but a significant reduction in hip fractures has not been demonstrated.
Movymia teriparatide is biosimilar to the reference teriparatide medicine. Biosimilarity means that the biological medicine has been shown to be highly similar in quality, biological activity, safety and effectiveness to its authorised reference product. It does not mean that different injection pens or cartridges are interchangeable: the Movymia cartridge must be used only in its dedicated reusable pen.
Who May Be Prescribed Movymia?
Approved adult uses include osteoporosis in postmenopausal women and men who are at increased fracture risk, and osteoporosis associated with long-term systemic glucocorticoid treatment in women and men at increased fracture risk. A specialist considers fracture history, bone density, age, previous osteoporosis treatment, steroid exposure, kidney function, calcium status and other causes of bone disease before prescribing.
Packaging and marketed presentations can differ between countries. The carton shown on this page is a European STADA presentation. Patients receiving a pack supplied through Turkey or another market should follow the local label, package leaflet, prescriber’s instructions and pharmacy cold-chain guidance.
Recommended Dose and 24-Month Lifetime Limit
The authorised dose is 20 micrograms once daily, corresponding to 80 microlitres, injected under the skin of the thigh or abdomen. The injection can be taken with or without food. It is helpful to use it at about the same time each day. Calcium and vitamin D may be prescribed if dietary intake is inadequate.
The maximum total duration of teriparatide treatment is 24 months, and that 24-month course should not be repeated during the patient’s lifetime. After the course finishes, the clinician may recommend another osteoporosis medicine to maintain the benefit. Never extend, repeat or restart Movymia teriparatide without the osteoporosis specialist reviewing the complete treatment history.
How to Use the Movymia Pen Safely
- Receive face-to-face training and read the Movymia Pen instructions before the first dose.
- Check the cartridge name, expiry date and clear, colourless appearance. There must be at least 28 days left before expiry when a new cartridge is started.
- Record the cartridge batch number and first-injection date on the carton or treatment calendar.
- Insert the cartridge into the reusable Movymia Pen. Prime a new cartridge only as described in the pen instructions before its first injection; do not prime before every dose.
- Attach a new compatible sterile needle, clean the chosen thigh or abdominal site, and inject under the skin as trained.
- Keep the push button pressed until the dose indicator returns to the starting position, then leave the needle in the skin for six seconds so the full dose can be delivered.
- Remove and safely discard the needle after every injection. Never store the pen with a needle attached.
- Leave the cartridge inside the pen for the full 28-day use period and return the pen immediately to the refrigerator.
Do not share the cartridge or pen, refill an empty cartridge, move the medicine to a syringe, inject it through another pen or use the Movymia Pen for insulin or any other medicine. Movymia teriparatide is a fixed-dose system; patients should never try to calculate a dose from cartridge volume.
Missed Dose, Stopping and Overdose
If a dose is forgotten, inject it as soon as possible on the same day. Do not inject more than once in a day and do not double the next dose. If an entire day has passed, resume the usual schedule the next day unless the prescriber advises otherwise. Discuss any plan to stop treatment because continuity and the follow-on osteoporosis plan matter.
If too much is injected, contact a doctor or pharmacist promptly. Expected overdose effects include nausea, vomiting, dizziness, headache, delayed high calcium and low blood pressure. There is no specific antidote; clinical assessment, serum-calcium monitoring, hydration and supportive care may be required.
9 Essential Safety Checks
- Confirm the indication: exclude other metabolic bone diseases and assess fracture risk before treatment.
- Check calcium status: do not use with pre-existing hypercalcaemia. Persistent nausea, vomiting, constipation, weakness or low energy can be warning symptoms.
- Review kidneys and stones: severe renal impairment is a contraindication; moderate impairment and active or recent kidney stones require caution.
- Exclude skeletal cancer risk: do not use with skeletal malignancy, bone metastases, prior radiation involving the skeleton, Paget’s disease or unexplained raised alkaline phosphatase.
- Plan for early dizziness: transient orthostatic hypotension can occur after the first doses. Inject where you can sit or lie down immediately.
- Review medicines: tell the clinician about digoxin or digitalis and all prescription, non-prescription and complementary products.
- Track the biological medicine: record the brand and batch number for every cartridge.
- Protect pregnancy and breastfeeding: use is contraindicated during pregnancy and breastfeeding; effective contraception is required for women who could become pregnant.
- Respect time and temperature: never exceed the 24-month lifetime course or the 28-day in-use period for one cartridge.
Monitoring During Treatment
The prescriber may review calcium, renal function, vitamin D status, fracture history and bone-density response according to the patient’s risk profile. Teriparatide can cause a small, temporary rise in serum calcium that peaks about four to six hours after injection and usually returns toward baseline by 16 to 24 hours. If serum calcium is measured, the SmPC advises taking the sample at least 16 hours after the most recent injection. Routine calcium testing is not required for every normocalcaemic patient, but symptoms and individual risks can justify closer monitoring.
Nutrition, sufficient protein, calcium and vitamin D, appropriate weight-bearing activity, balance training, smoking cessation, alcohol moderation and fall-risk reduction complement the medicine. These measures should be individualised, particularly after a recent fracture or in people with mobility limitations.
Side Effects and When to Get Help
The most frequently reported effects are limb pain, nausea, headache and dizziness. Injection-site redness, pain, swelling, itching, bruising or minor bleeding can occur. Other reported effects include fatigue, muscle cramps, palpitations, low blood pressure, anaemia, heartburn, vomiting, increased sweating, raised cholesterol and back, muscle or joint pain.
Sit or lie down if light-headed after an injection. Obtain urgent medical help for difficulty breathing, facial or throat swelling, widespread rash, severe chest symptoms or signs of anaphylaxis. Contact the clinician for persistent symptoms of high calcium, fainting, severe back cramps, new kidney-stone symptoms, reduced urine output or an injection-site reaction that does not improve.
Who Must Not Use Movymia?
Movymia teriparatide is contraindicated in people with allergy to teriparatide or an excipient, pre-existing hypercalcaemia, severe renal impairment, metabolic bone disease other than primary or glucocorticoid-induced osteoporosis, unexplained raised alkaline phosphatase, prior external-beam or implant radiation involving the skeleton, skeletal malignancy or bone metastases, pregnancy or breastfeeding. It should not be used in children, adolescents under 18 or young adults whose growth plates remain open.
Refrigerated Storage and the 28-Day Rule
- Store unopened cartridges in a refrigerator at 2–8°C inside the outer carton to protect them from light.
- Do not freeze and do not place the cartridge close to the freezer compartment. Do not use it if it has frozen.
- After the first injection, keep the cartridge inserted in the pen and refrigerate the combined pen and cartridge immediately after every use.
- Never leave a needle attached during storage.
- Discard the cartridge 28 days after its first use even if solution remains.
- Do not use solution that is cloudy, coloured or contains particles.
Frequently Asked Questions
Is Movymia a daily injection?
Yes. The authorised regimen is one fixed 20 microgram subcutaneous dose every day, prescribed and supervised by the treating clinician.
Can I use the cartridge with an insulin pen?
No. The cartridge is authorised exclusively for the reusable Movymia Pen. Transferring it to a syringe or another pen risks a serious dosing error.
Why is the cartridge discarded after 28 days?
The official in-use stability is 28 days at 2–8°C. It must be discarded at the end of that period even when it is not completely empty.
Does Movymia treat every type of osteoporosis?
No. Eligibility depends on the approved indication, fracture risk and exclusion of other bone disorders. The prescriber makes that assessment.
Can the 24-month course be repeated?
No. The authorised information states that total teriparatide treatment should not exceed 24 months and should not be repeated over the patient’s lifetime.
Official Medical Sources
- European Medicines Agency: Movymia EPAR and current product information
- Movymia Summary of Product Characteristics
- Movymia official patient information leaflet
- Movymia patient training resources
Explore more evidence-based health information at No Style Like. Medical disclaimer: this page is educational and does not replace the local leaflet, injection training or advice from the prescribing clinician and pharmacist. Do not start, stop, repeat or change Movymia teriparatide without professional supervision.
Reviews
There are no reviews yet.